Waveform Technologies Inc.

Trinity Biotech Secures $7.0 Million Investment from Perceptive Advisors and Regains Nasdaq Compliance

- Trinity Biotech secured approximately $7.0 million in additional investment from funds managed by Perceptive Advisors, its largest financial investor and primary lender. - The funding comprises roughly $2.5 million of new debt and $4.5 million of capitalised interest under an amendment to existing financing arrangements. - Trinity Biotech regained compliance with Nasdaq's minimum bid price requirement, with its ADS closing at $1.00 or greater for 10 consecutive business days. - The capital supports strategic initiatives including the CGM+ continuous glucose monitoring platform, the Trinovium subsidiary, and the company's broader business transformation.